For research use only. Not for therapeutic Use.
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells[1][2].
Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells from peripheral blood mononuclear cell (PBMC)/BMMC samples from cynomolgus monkey[1].
Cevostamab (0.5 mg/kg; i.v.; once weekly for ) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells[1].
| Catalog Number | I042114 |
| CAS Number | 2249888-53-5 |
| Purity | ≥95% |
| Reference | [1]. Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017 Mar 13;31(3):383-395. [2]. Hosny M, et al. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med. 2021 Oct 6;10(19):4593. |
